Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

1. www.youtube.com › watchEIGR Stock: Huge 52-Week Low Plunge On Heavy Volume. Two ... -...

   www.youtube.com › watch

   • Αποθηκευμένο αντίγραφο

   EIGR price reached a new 52-week low of $0.96. Trading volume exceeded the 10-day average of 974,369 by 238.79%.Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR),...

2. www.youtube.com › watch34% Collective Loss | EIGR Stock News | Eiger ... - YouTube

   www.youtube.com › watch

   • Αποθηκευμένο αντίγραφο

   Deadline January 9, 2023, Learn More 👉 https://bit.ly/EIGR-NASDAQ 34% Collective Loss | EIGR Stock News | Eiger BioPharmaceuticals Inc Securities Class Ac...

3. www.youtube.com › @OprahOprah - YouTube

   www.youtube.com › @Oprah

   • Αποθηκευμένο αντίγραφο

   Official Youtube channel for Oprah Winfrey. Oprah is a global media leader, producer, philanthropist, actress and author.

4. ca.finance.yahoo.com › quote › EIGREiger BioPharmaceuticals, Inc. (EIGR) Latest Stock News &...

   ca.finance.yahoo.com › quote › EIGR

   • Αποθηκευμένο αντίγραφο

   Get the latest Eiger BioPharmaceuticals, Inc. (EIGR) stock news and headlines to help you in your trading and investing decisions.

5. www.fool.com › quote › nasdaqEiger BioPharmaceuticals - EIGR - Stock Price & News | The Motley...

   www.fool.com › quote › nasdaq

   • Αποθηκευμένο αντίγραφο

   Real time Eiger BioPharmaceuticals (EIGR) stock price quote, stock graph, news & analysis.

6. www.marketscreener.com › quote › stockEiger BioPharmaceuticals Stock (EIGR) - Quote OTC Markets-...

   www.marketscreener.com › quote › stock

   • Αποθηκευμένο αντίγραφο

   27 Σεπ 2024 · Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Eiger BioPharmaceuticals | OTC Markets: EIGR | OTC Markets.

7. stocknews.com › stock › EIGREIGR News: Earnings, Analyst Moves, and More - StockNews

   stocknews.com › stock › EIGR

   • Αποθηκευμένο αντίγραφο

   Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the third quarter 2023 and provided a business update.